Cardiovascular outcome trials (CVOTs) in cardiorenal metabolic medicine: a decade of transformative progress (2016-2026)
Wen S, Wang C, Xu Z, et al.
Cardiovasc Diabetol. Pub. online 24 Apr 2026.
Leggi
Blu
Le Breaking News di colore blu sono relative ad abstract di articoli originali di particolare rilevanza.
Implementation of sodium-glucose co-transporter 2 inhibitors use in patients with heart failure across the ejection fraction: data from the Swedish heart failure registry
Ferrannini G, Musella F, Benson L, et al.
Eur Heart J Qual Care Clin Outcomes. Pub. online 19 Apr 2026.
Leggi
Low uptake and disparities in therapeutic inertia of cardiorenal protective diabetes medications for patients with type 2 diabetes and above-target hemoglobin A1c
German J, Huang WA, Brucker A, et al.
BMJ Open Diabetes Res Care. Pub. online 22 Apr 2026.
Leggi
Feasibility of using OGTT 1-h PG as a diagnostic criterion for diabetes and pre-diabetes
Chen L, Bian B, Ran H, et al.
BMJ Open Diabetes Res Care. Pub. online 22 Apr 2026.
Leggi
Novel OGTT metrics do not provide incremental predictive value beyond conventional glycemic criteria for remission of prediabetes in individuals with impaired fasting glucose: results from the PREVIEW trial
Zhu R, Guo J, Stratton G, et al.
Cardiovasc Diabetol. Pub. online 22 Apr 2026.
Leggi
Evaluation of large language models for carbohydrate counting in type 1 diabetes mellitus: a comparative study with patient estimations
Soyer AK, Akarsu GÇ, Yelli BD, et al.
Diabetes Res Clin Pract. Pub. online 25 Apr 2026.
Leggi
Efficacy and safety of anagliptin added to metformin and empagliflozin 25 mg in patients with type 2 diabetes: a 24-week randomized, double-blind, placebo-controlled phase 3 trial with 28-week open-label extension
Moon JS, Han KA, Yu JM, et al.
Diabetes Res Clin Pract. Pub. online 24 Apr 2026.
Leggi
Age- and sex-specific trends in dementia mortality among people with and without diabetes: a multi-country population-based analysis
Mehta K, Morton JI, Chen L, et al.
Diabetologia. Pub. online 21 Apr 2026.
Leggi
Continuous glucose monitoring versus self-monitoring of blood glucose in individuals with type 2 diabetes: a randomised, multicentre, open-label, superiority trial
Wilmot EG, Moore P, Sathyapalan T, et al.
Lancet Diabetes Endocrinol. Pub. online 23 Apr 2026.
Leggi
Efficacy, safety and PK of once-daily oral semaglutide 25 mg for obesity with and without type 2 diabetes in comparison with subcutaneous semaglutide 2.4 mg: a model-informed drug development approach
Overgaard RV, Birkhan O, Rathor N, et al.
Diabetes Obes Metab. Pub. online 23 Apr 2026.
Leggi